BioLife Solutions (NASDAQ:BLFS) CFO Troy Wichterman Sells 1,033 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $25.13, for a total transaction of $25,959.29. Following the completion of the sale, the chief financial officer owned 151,736 shares in the company, valued at $3,813,125.68. The trade was a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Troy Wichterman also recently made the following trade(s):

• On Thursday, December 4th, Troy Wichterman sold 30,000 shares of BioLife Solutions stock. The stock was sold at an average price of $25.72, for a total value of $771,600.00.
• On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The stock was sold at an average price of $26.74, for a total value of $15,616.16.
• On Thursday, October 9th, Troy Wichterman sold 833 shares of BioLife Solutions stock. The shares were sold at an average price of $27.36, for a total value of $22,790.88.

BioLife Solutions Stock Up 1.6%

BLFS stock traded up $0.40 during trading on Wednesday, reaching $25.01. 296,709 shares of the company’s stock were exchanged, compared to its average volume of 445,500. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The firm has a market cap of $1.20 billion, a PE ratio of -357.23 and a beta of 1.93. The company’s fifty day moving average price is $26.39 and its 200-day moving average price is $24.51.

Wall Street Analyst Weigh In

BLFS has been the topic of several research analyst reports. Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Sunday, November 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of BioLife Solutions in a report on Monday, November 24th. Finally, Zacks Research downgraded BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $30.75.

Institutional Trading of BioLife Solutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming lifted its stake in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,490 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of BioLife Solutions by 54.1% in the third quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after buying an additional 659 shares in the last quarter. US Bancorp DE lifted its position in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 1,528 shares during the last quarter. Quarry LP lifted its position in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 713 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its stake in shares of BioLife Solutions by 12.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 441 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.